Which criterion is used to assess validity of evidence about prognostic factors to avoid heterogeneity?

Which criterion is used to assess validity of evidence about prognostic factors to avoid heterogeneity?

• A. Was the study randomized?
• B. Did all subjects enter at the same stage of their condition?
• C. Were outcomes blinded to prognostic factor status?
• D. Was the sample size adequate?

Answer: (B)

When evaluating evidence about prognostic factors, reducing variation that can blur true associations is essential. If patients are at different stages of their disease, the same prognostic factor can behave differently, making results look inconsistent or non-generalizable. Ensuring that all subjects enter at the same stage of their condition directly limits this heterogeneity, so the observed relationship between the factor and outcomes more faithfully reflects its prognostic value rather than differences in disease progression. Other considerations address different biases or issues but don’t tackle this source of heterogeneity. Randomization helps with treatment allocation bias, not stage-related variation in prognosis. Blinding outcome assessment to factor status reduces measurement bias but doesn’t harmonize disease stage across participants. Adequate sample size improves precision but doesn’t fix stage-related differences that confound prognostic effects.

When evaluating evidence about prognostic factors, reducing variation that can blur true associations is essential. If patients are at different stages of their disease, the same prognostic factor can behave differently, making results look inconsistent or non-generalizable. Ensuring that all subjects enter at the same stage of their condition directly limits this heterogeneity, so the observed relationship between the factor and outcomes more faithfully reflects its prognostic value rather than differences in disease progression.

Other considerations address different biases or issues but don’t tackle this source of heterogeneity. Randomization helps with treatment allocation bias, not stage-related variation in prognosis. Blinding outcome assessment to factor status reduces measurement bias but doesn’t harmonize disease stage across participants. Adequate sample size improves precision but doesn’t fix stage-related differences that confound prognostic effects.